Improved synthesis strategy for peptide nucleic acids (PNA) appropriate for cell-specific fluorescence imaging

International Journal of Medical Sciences

Volumn 9, Issue 1, 2012, Pages 1-10

  Pipkorn, Rüdiger ^a   Wiessler, Manfred ^a   Waldeck, Waldemar ^a   Hennrich, Ute ^a   Nokihara, Kiyoshi ^b   Beining, Marcel ^a   Braun, Klaus ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b HiPep Laboratories   (Japan)

Author keywords

Click chemistry; Fluorescence imaging; Peptide nucleic acid (PNA); PNA building block functionalization

Indexed keywords

CATHEPSIN B; MESSENGER RNA; PEPTIDE NUCLEIC ACID;

ARTICLE; CELL LINE; CELL SPECIFICITY; CONTROLLED STUDY; CTSB GENE; CYTOPLASM; FLUORESCENCE IMAGING; GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; NUCLEIC ACID SYNTHESIS; NUCLEOTIDE SEQUENCE; PROTEIN CLEAVAGE; RNA SEQUENCE; SOLID PHASE SYNTHESIS;

EID: 82055197306     PISSN: 14491907     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijms.9.1     Document Type: Article

References (83)

1. Miller L. A Production of Amino Acids Under Possible Primitive Earth Conditions. Science. 1953; 117: 528-9.
2. Miller SL. Peptide nucleic acids and prebiotic chemistry. Nat Struct Biol. 1997; 4: 167-9.
3. Bohler C, Nielsen PE, Orgel LE. Template switching between PNA and RNA oligonucleotides. Nature. 1995; 376: 578-81.
4. Nielsen PE. Peptide nucleic acids and the origin of life. Chem Biodivers. 2007; 4: 1996-2002.
5. Nelson KE, Levy M, Miller SL. Peptide nucleic acids rather than RNA may have been the first genetic molecule. Proc Natl Acad Sci U S A. 2000; 97: 3868-71.
6. [Internet] Miller SL. Prebiotic. http://exobio.ucsd.edu.
7. Nielsen PE, Egholm M, Berg RH, et al. Sequence-selective recognition of DNA by strand displacement with a thymine-substituted polyamide. Science. 1991; 254: 1497-500.
8. Merriefield RB. Solid Phase Peptide Synthesis. I The Synthesis of a Tetrapeptide. J Americ Chem Soc. 1963; 85: 2149-54.
9. Carpino LA, Han GY. The 9-Fluorenylmethoxycarbonyl Amino-Protecting Group. J ORG CHEM. 1972; 37: 3404-9.
10. Galanis AS, Albericio F, Grotli M. Solid-phase peptide synthesis in water using microwave-assisted heating. Org Lett. 2009; 11: 4488-91.
11. Pedersen SL, Sorensen KK, Jensen KJ. Semi-automated microwave-assisted SPPS: Optimization of protocols and synthesis of difficult sequences. Biopolymers. 2010; 94: 206-12.
12. Hojo K, Maeda M, Tanakamaru N, et al. Solid phase peptide synthesis in water VI: evaluation of water-soluble coupling reagents for solid phase peptide synthesis in aqueous media. Protein Pept Lett. 2006; 13: 189-92.
13. Sabatino G, Papini AM. Advances in automatic, manual and microwave-assisted solid-phase peptide synthesis. Curr Opin Drug Discov Devel. 2008; 11: 762-70.
14. Moss JA. Guide for resin and linker selection in solid-phase peptide synthesis. Curr Protoc Protein Sci. 2005; Chapter 18: Unit 18.7.
15. Amblard M, Fehrentz JA, Martinez J, et al. Fundamentals of modern peptide synthesis. Methods Mol Biol. 2005; 298: 3-24.
16. Good L, Nielsen PE. Antisense inhibition of gene expression in bacteria by PNA targeted to mRNA. Nat Biotechnol. 1998; 16: 355-8.
17. Ecker DJ, Freier SM. PNA, antisense, and antimicrobials. Nat Biotechnol. 1998; 16: 332.
18. Frank Kamenetskii MD, Mirkin SM. Triplex DNA structures. Annu Rev Biochem. 1995; 64: 65-95.
19. Nielsen PE. Targeting double stranded DNA with peptide nucleic acid (PNA). Curr Medicinal Chem. 2001; 8: 545-50.
20. Casey BP, Glazer PM. Gene targeting via triple-helix formation. Prog Nucleic Acid Res Mol Biol. 2001; 67: 163-92.
21. Agrawal S, Iyer RP. Modified oligonucleotides as therapeutic and diagnostic agents. Curr Opin Biotechnol. 1995; 6: 12-9.
22. Arlinghaus HF, Kwoka MN, Jacobson KB. Analysis of biosensor chips for identification of nucleic acids. Anal Chem. 1997; 69: 3747-53.
23. Leijon M, Graslund A, Nielsen PE, et al. Structural characterization of PNA-DNA duplexes by NMR. Evidence for DNA in a B-like conformation. Biochemistry. 1994; 33: 9820-5.
24. Eriksson M. Structure of PNA-Nucleic Acid Complexes. Nucleos Nucleot. 1997; 16: 617-21.
25. Demidov VV, Potaman VN, Frank Kamenetskii MD, et al. Stability of peptide nucleic acids in human serum and cellular extracts. Biochem Pharmacol. 1994; 48: 1310-3.
26. Nielsen PE, Christensen L. Strand Displacement Binding of a Duplex-Forming Homopurine PNA to a Homopyrimidine Duplex DNA Target. J AMER CHEM SOC. 1996; 118: 2287-8.
27. Eriksson M, Nielsen PE. PNA-nucleic acid complexes. Structure, stability and dynamics. Q Rev Biophys. 1996; 29: 369-94.
28. Nielsen PE. Peptide nucleic acids (PNA) in chemical biology and drug discovery. Chem Biodivers. 2010; 7: 786-804.
29. Dueholm KL, Egholm M, Behrens C, et al. Synthesis of Peptide Nucleic Acid Monomers Containing the Four Natural Nucleobases: Thymine, Cytosine, Adenine, and Guanine and their Oligomerization. J ORG CHEM. 1994; 59: 5767-73.
30. Fader LD, Myers EL, Tsantrizos YS. Synthesis of novel analogs of aromatic peptide nucleic acids (APNAs) with modified conformational and electrostatic properties. TETRAHEDRON. 2004; 60: 2235-46.
31. Egholm M, Buchardt O, Nielsen PE, et al. Peptide Nucleic Acids (PNA). Oligonucleotide Analogues with an Achiral Peptide Backbone. J Am Chem Soc. 1992; 114: 1895-7.
32. Buchardt O, Egholm M, Berg RH, et al. Peptide nucleic acids and their potential applications in biotechnology. Trends Biotechnol. 1993; 11: 384-6.
33. Nielsen PE, Haaima G. Peptide Nucleic-Acid (PNA) - A DNA Mimic with a Pseudopeptide Backbone. CHEM SOC REV. 1997; 26: 73-8.
34. Dueholm KL, Nielsen PE. Chemistry, Properties and Applications of PNA (Peptide Nucleic- Acid). NEW J CHEM. 1997; 21: 19-31.
35. Jordan S, Schwemler C, Kosch W, et al. Synthesis of New Building-Blocks for Peptide Nucleic-Acids Containing Monomers with Variations in the Backbone. Bioorg Medicinal Chem Letter. 1997; 7: 681-6.
36. Wu J, Xu XY, Liu KL. Synthesis of new chiral building blocks for novel peptide nucleic acids. Chinese Journal of Chemistry. 2003; 21: 566-73.
37. Wiessler M, Waldeck W, Pipkorn R, et al. Extension of the PNA world by functionalized PNA monomers eligible candidates for inverse Diels Alder Click Chemistry. Int J Med Sci. 2010; 7: 213-23.
38. Wiessler M, Waldeck W, Kliem C, et al. The Diels-Alder-reaction with inverse-electron-demand, a very efficient versatile click-reaction concept for proper ligation of variable molecular partners. Int J Med Sci. 2009; 7: 19-28.
39. Braun K, Ehemann V, Wiessler M, et al. High-Resolution Flow Cytometry: a Suitable Tool for Monitoring Aneuploid Prostate Cancer Cells after TMZ and TMZ-BioShuttle Treatment. Int J Med Sci. 2009; 6: 338-47.
40. Kolb HC, Sharpless KB. The growing impact of click chemistry on drug discovery. Drug Discov Today. 2003; 8: 1128-37.
41. Rostovtsev VV, Green LG, Fokin VV, et al. A stepwise huisgen cycloaddition process: copper(I)-catalyzed regioselective ligation of azides and terminal alkynes. Angew Chem Int Ed Engl. 2002; 41: 2596-9.
42. El-Sagheer AH, Brown T. Click chemistry with DNA. Chem Soc Rev. 2010; 39: 1388-405.
43. Carboni RA, Lindsey RV. Reactions of Tetrazines with Unsaturated Compounds - A New Synthesis of Pyridazines. J Americ Chem So. 1959; 81: 4342-6.
44. Sauer J, Wiest H. Diels-Alder-Additionen Mit Inversem Elektronenbedarf. Angewandte Chemie-International Edition. 1962; 74: 353.
45. Lin FL, Hoyt HM, van HH, et al. Mechanistic investigation of the staudinger ligation. J Am Chem Soc. 2005; 127: 2686-95.
46. Chang PV, Prescher JA, Sletten EM, et al. Copper-free click chemistry in living animals. Proc Natl Acad Sci U S A. 2010; 107: 1821-6.
47. Braun K, Wiessler M, Ehemann V, et al. Treatment of glioblastoma multiforme cells with temozolomide-BioShuttle ligated by the inverse Diels-Alder ligation chemistry. Drug Design, Development and Therapy. 2008; 2: 289-301.
48. Waldeck W, Wiessler M, Ehemann V, et al. TMZ-BioShuttle--a reformulated temozolomide. Int J Med Sci. 2008; 5: 273-84.
49. Pipkorn R, Waldeck W, Didinger B, et al. BioShuttle as a carrier for temozolomide transport into prostate cancer cells. Journal of Peptide Science. 2008; 14: 156.
50. Pipkorn R, Wiessler M, Waldeck W, et al. Tmz-Bioshuttle, An Exemplary Drug Reformulation by Inverse Diels Alder Click Chemistry. Biopolymers. 2009; 92: 350-1.
51. Braun K, Dunsch L, Pipkorn R, et al. Gain of a 500-fold sensitivity on an intravital MR contrast agent based on an endohedral gadolinium-cluster-fullerene-conjugate: a new chance in cancer diagnostics. Int J Med Sci. 2010; 7: 136-46.
52. Braun K, Wiessler M, Pipkorn R, et al. A cyclic-RGD-BioShuttle functionalized with TMZ by DARinv Click Chemistry targeted to alphavbeta3 integrin for therapy. Int J Med Sci. 2010; 7: 326-39.
53. Warner S. Diagnostics + Therapy = Theranostics. The Scientist. 2004; 18: 38.
54. Braun K, Peschke P, Pipkorn R, et al. A biological transporter for the delivery of peptide nucleic acids (PNAs) to the nuclear compartment of living cells. J Mol Biol. 2002; 318: 237-43.
55. Pipkorn R, Waldeck W, Spring H, et al. Delivery of substances and their target-specific topical activation. Biochim Biophys Acta. 2006; 1758: 606-10.
56. Dolphin GT. A designed well-folded monomeric four-helix bundle protein prepared by Fmoc solid-phase peptide synthesis and native chemical ligation. Chemistry. 2006; 12: 1436-47.
57. Macville M, Schrock E, Padilla-Nash H, et al. Comprehensive and definitive molecular cytogenetic characterization of HeLa cells by spectral karyotyping. Cancer Res. 1999; 59: 141-50.
58. Baker CC, Phelps WC, Lindgren V, et al. Structural and transcriptional analysis of human papillomavirus type 16 sequences in cervical carcinoma cell lines. J Virol. 1987; 61: 962-71.
59. Cailleau R, Young R, Olive M, et al. Breast tumor cell lines from pleural effusions. J Natl Cancer Inst. 1974; 53: 661-74.
60. Young RK, Cailleau RM, Mackay B, et al. Establishment of epithelial cell line MDA-MB-157 from metastatic pleural effusion of human breast carcinoma. In Vitro. 1974; 9: 239-45.
61. Baici A, Lang A, Horler D, et al. Cathepsin B as a marker of the dedifferentiated chondrocyte phenotype. Ann Rheum Dis. 1988; 47: 684-91.
62. Foghsgaard L, Wissing D, Mauch D, et al. Cathepsin B acts as a dominant execution protease in tumor cell apoptosis induced by tumor necrosis factor. J Cell Biol. 2001; 153: 999-1010.
63. Mohanam S, Jasti SL, Kondraganti SR, et al. Down-regulation of cathepsin B expression impairs the invasive and tumorigenic potential of human glioblastoma cells. Oncogene. 2001; 20: 3665-73.
64. Zwicky R, Muntener K, Goldring MB, et al. Cathepsin B expression and down-regulation by gene silencing and antisense DNA in human chondrocytes. Biochem J. 2002; 367: 209-17.
65. Drews J, Ryser S. The role of innovation in drug development. Nat Biotechnol. 1997; 15: 1318-9.
66. Werner RG. Biobusiness in the pharmaceutical industry. Arzneimittelforschung. 1987; 37: 1086-93.
67. Farber GK. New approaches to rational drug design. Pharmacol Ther. 1999; 84: 327-32.
68. Roth CM, Yarmush ML. Nucleic acid biotechnolqgy. Annu Rev Biomed Eng. 1999; 1: 265-97.
69. Hogemann D, Basilion JP. Seeing inside the body: MR imaging of gene expression. Eur J Nucl Med. 2002; 29: 400-8.
70. Okubo K, Matsumoto K, Ssito H. Omics study of diseases. Nihon Jibiinkoka Gakkai Kaiho. 2011; 114: 51-9.
71. Farooqi AA, Bhatti S, Nawaz A, et al. One size fits all in prostate cancer: a story tale whose time has come and gone. Int J Biol Markers. 2011; 26: 75-81.
72. Swain SM. Chemotherapy: updates and new perspectives. Oncologist. 2011; 16 (Suppl 1): 30-9.
73. Garnier JP. Rebuilding the R&D engine in big pharma. Harv Bus Rev. 2008; 86: 68-76.
74. Badcott D. Some causal limitations of pharmacogenetic concepts. Med Health Care Philos. 2006; 9: 307-16.
75. Diamandis M, White NM, Yousef GM. Personalized medicine: marking a new epoch in cancer patient management. Mol Cancer Res. 2010; 8: 1175-87.
76. Gibson WM. Can personalized medicine survive? Can Fam Physician. 1971; 17: 29-88.
77. Kawamoto K, Lobach DF, Willard HF, et al. A national clinical decision support infrastructure to enable the widespread and consistent practice of genomic and personalized medicine. BMC Med Inform Decis Mak. 2009; 9: 17.
78. Lavis J, Ross S, McLeod C, et al. Measuring the impact of health research. J Health Serv Res Policy. 2003; 8: 165-70.
79. Rathore AS. Roadmap for implementation of quality by design (QbD) for biotechnology products. Trends Biotechnol. 2009; 27: 546-53.
80. Palasek SA, Cox ZJ, Collins JM. Limiting racemization and aspartimide formation in microwave-enhanced Fmoc solid phase peptide synthesis. J Pept Sci. 2007; 13: 143-8.
81. Bacsa B, Horvati K, Bosze S, et al. Solid-phase synthesis of difficult peptide sequences at elevated temperatures: a critical comparison of microwave and conventional heating technologies. J Org Chem. 2008; 73: 7532-42.
82. Nokihara K, Yamamoto S, Toda C, Wang J. Development of a simple and low cost manual synthsizer for chemical library construction. In: Aoyagi H, editor. Peptide Science. Japan: The Japanese Peptide Society. 2001: 61-4.
83. Tam JP, Riemen MW, Merrifield RB. Mechanisms of aspartimide formation: the effects of protecting groups, acid, base, temperature and time. Pept Res. 1988; 1: 6-18.